Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sanofi's new insulin Toujeo is just months away from a European approval as the CHMP has recommended the drug for use across the continent.
Once-daily Toujeo (insulin glargine [rDNA origin]) is a next generation version of Sanofi's blockbuster insulin Lantus, which has been bringing in more than $8bn a year for the firm.
But patents for Lantus are set to fall across key markets later this year, and rival big pharma firm Lilly is poised to release a biosimilar version of the treatment, which could cut its sales - although launch of the copycat has been delayed from its original May 2015 date.
Just how much of a threat the biosimilar will turn out to be remains to be seen, but Toujeo will be a key new treatment for the firm as falling sales of Lantus - and diabetes treatments in general - start to bite.
http://www.pmlive.com/pharma_news/sanofis_lantus_follow-up_nears_european_approval_665680
Once-daily Toujeo (insulin glargine [rDNA origin]) is a next generation version of Sanofi's blockbuster insulin Lantus, which has been bringing in more than $8bn a year for the firm.
But patents for Lantus are set to fall across key markets later this year, and rival big pharma firm Lilly is poised to release a biosimilar version of the treatment, which could cut its sales - although launch of the copycat has been delayed from its original May 2015 date.
Just how much of a threat the biosimilar will turn out to be remains to be seen, but Toujeo will be a key new treatment for the firm as falling sales of Lantus - and diabetes treatments in general - start to bite.
http://www.pmlive.com/pharma_news/sanofis_lantus_follow-up_nears_european_approval_665680
